In a Journal of Clinical Psychiatry webinar, Kristina Deligiannidis, MD, framed the clinical problem that drives her research: peripartum depression affects up to one in four women, yet the treatment cascade leaks at every step. Of a hypothetical 100 postpartum women in the US, roughly 20 have peripartum depression, only 10 to 15 are screened, 6 to 10 are diagnosed, 4 to 6 begin treatment, and just 2 to 3 receive an adequate dose and duration. The consequences of undertreatment are severe: perinatal mental health disorders are a leading cause of pregnancy-related death, and a CDC review across 36 states found that every death from suicide or overdose was deemed preventable. That reality, she argued, is the case for faster, better-tolerated treatments with shorter courses.
SSRIs remain the community mainstay but show only modest benefit over placebo in postpartum trials and high discontinuation rates, with 63 to 76 percent of women stopping treatment within a year. The neuroactive steroids marked a shift: brexanolone (approved 2019, a 60-hour IV infusion, since withdrawn) and zuranolone (approved 2023, a 14-day oral course), both with rapid onset and very low passage into breast milk. Against that backdrop, Dr. Deligiannidis presented GH001, a synthetic, inhaled form of mebufotenin (5-MeO-DMT) and a non-selective serotonin agonist with high 5-HT1A affinity. Its defining practical feature is a psychoactive experience lasting a median of just 11 minutes, which could lower the supervision burden that makes many psychedelic therapies hard to access for mothers of infants.
The phase 2a trial was small and preliminary: single-arm, open-label, 10 women with moderate-to-severe postpartum depression (mean MADRS 36.7), dosed with an individualized regimen and no accompanying psychotherapy. All 10 achieved remission by day 8, with a mean MADRS reduction of 35.4 points, and maternal functioning on the BIMF improved 56 percent, with gains across six of seven domains. In a breast-milk sub-study, mebufotenin and its metabolites were cleared to below quantification by about eight hours post-dose. GH001 was generally well tolerated (most commonly transient headache), with no serious adverse events and same-day discharge readiness. Dr. Deligiannidis was explicit about the limits, no control arm, no blinding, one-week follow-up, ten patients, and framed the results as proof of concept pointing toward a broader goal: a personalized toolkit for PPD rather than a single default.
